Abbott Laboratories (ABT): who owns it and who trades it
As of Nov 16, 2026, ABT insiders reported 12 open-market sales worth $47.9M and 6 purchases worth $4.4M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Robert B Ford (CEO), with $46.2M. 10 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Abbott Laboratories
From the latest filingsOverall: more selling than buying. Insiders, famous investors and Congress mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ABT
2,951 funds and institutions reported ABT shares worth $125B at the end of Q2 2026, about 80% of the company. The largest holder is BlackRock, Inc. with 8.8%.
Funds and institutions (13F) 80%Everyone else 20%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 152.56M | 8.82% | $13.8B | +5% |
| Vanguard Capital Management LLC | 113.75M | 6.57% | $10.3B | +1% |
| State Street Corp | 80.93M | 4.68% | $7.3B | +2% |
| Charles Schwab Investment Management Inc | 59.67M | 3.45% | $5.4B | +31% |
| Vanguard Portfolio Management LLC | 49.02M | 2.83% | $4.4B | +2% |
| Geode Capital Management, LLC | 39.22M | 2.27% | $3.5B | +0% |
| Capital Research Global Investors | 36.91M | 2.13% | $3.3B | -26% |
| Capital International Investors | 34.65M | 2.00% | $3.1B | -8% |
| Morgan Stanley | 26.61M | 1.54% | $2.4B | -12% |
| Norges Bank | 23.35M | 1.35% | $2.1B | – |
| T. Rowe Price Associates | 22.79M | 1.32% | $2.1B | +32% |
| Franklin Resources Inc | 18.81M | 1.09% | $1.7B | -6% |
| Northern Trust Corp | 18.27M | 1.06% | $1.7B | -6% |
| Bank of America Corp | 17.67M | 1.02% | $1.6B | -8% |
| Goldman Sachs Group Inc | 16.76M | 0.97% | $1.5B | +16% |
| Deutsche Bank Ag\ | 16.71M | 0.97% | $1.5B | +19% |
| Wells Fargo & Company | 15.18M | 0.88% | $1.4B | -5% |
| JPMorgan Chase & Co | 15.10M | 0.87% | $1.4B | – |
| State Farm Mutual Automobile Insurance Co | 13.59M | 0.79% | $1.2B | No change |
| FMR LLC (Fidelity) | 13.42M | 0.78% | $1.2B | +24% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ABT insiders reported $4.4M of open-market purchases and $47.9M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Mary K Moreland | Vice president | Sale | 3,500 | $116.00 | $406K | Form 4 |
| Sep 2, 2026 | John A. Mccoy Jr. | Vice president | Sale | 27 | $109.54 | $3K | Form 4 |
| Aug 25, 2026 | Robert B Ford | CEO | Sale | 218,535 | $115.57 | $25.3M | Form 4 |
| Aug 25, 2026 | Robert B Ford | CEO | Sale | 180,297 | $116.19 | $20.9M | Form 4 |
| Aug 11, 2026 | Louis H. Morrone | Vice president | Sale | 5,850 | $109.83 | $643K | Form 4 |
| May 7, 2026 | John G Stratton | Director | Purchase | 2,000 | $86.82 | $174K | Form 4 |
| Apr 27, 2026 | Daniel J Starks | Director | Purchase | 10,000 | $92.65 | $926K | Form 4 |
| Apr 23, 2026 | Philip P Boudreau | CFO | Purchase | 2,200 | $91.50 | $201K | Form 4 |
| Mar 2, 2026 | Eric Shroff | Vice president | Sale | 709 | $115.58 | $81.9K | Form 4 |
| Mar 2, 2026 | Daniel Gesua Sive Salvadori | Vice president | Sale | 885 | $115.58 | $102K | Form 4 |
| Mar 2, 2026 | Louis H. Morrone | Vice president | Sale | 1,144 | $115.58 | $132K | Form 4 |
| Mar 2, 2026 | Mary K Moreland | Vice president | Sale | 613 | $115.58 | $70.9K | Form 4 |
| Mar 2, 2026 | John A. Mccoy Jr. | Vice president | Sale | 585 | $115.58 | $67.6K | Form 4 |
| Mar 2, 2026 | Elizabeth C. Cushman | Vice president | Sale | 263 | $115.58 | $30.4K | Form 4 |
| Feb 4, 2026 | Daniel J Starks | Director | Purchase | 5,033 | $108.33 | $545K | Form 4 |
| Feb 4, 2026 | Daniel J Starks | Director | Purchase | 4,967 | $109.14 | $542K | Form 4 |
| Jan 23, 2026 | Robert B Ford | CEO | Purchase | 18,800 | $107.13 | $2M | Form 4 |
| Nov 25, 2025 | Eric Shroff | Vice president | Sale | 1,586 | $128.02 | $203K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Robert B Ford | CHAIRMAN AND CEO, Director | $2M | $46.2M | Aug 25, 2026 |
| Daniel J Starks | Director | $2M | – | Apr 27, 2026 |
| Louis H. Morrone | EXECUTIVE VICE PRESIDENT | – | $775K | Aug 11, 2026 |
| Mary K Moreland | EXECUTIVE VICE PRESIDENT | – | $477K | Nov 5, 2026 |
| Eric Shroff | Senior Vice President | – | $285K | Mar 2, 2026 |
| Philip P Boudreau | EVP AND CFO | $201K | – | Apr 23, 2026 |
| John G Stratton | Director | $174K | – | May 7, 2026 |
| Daniel Gesua Sive Salvadori | EVP AND GROUP PRESIDENT | – | $102K | Mar 2, 2026 |
| John A. Mccoy Jr. | VICE PRESIDENT AND CONTROLLER | – | $70.6K | Sep 2, 2026 |
| Elizabeth C. Cushman | EVP, GC AND SECRETARY | – | $30.4K | Mar 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ABT short interest
Low short interest. 1.1% of ABT shares are sold short: about 1 share in 91. Over the last 12 reports the number of shares short went down 18%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 19.06M ABT shares were sold short, 1.1% of the shares outstanding, up 9.6% from the report before. At the average daily volume of 9.96M shares, buying them all back would take about 1.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 19.06M | 1.10% | +10% | 9.96M | 1.9 |
| Oct 15, 2026 | 17.39M | 1.00% | +28% | 9.77M | 1.8 |
| Sep 30, 2026 | 13.63M | 0.79% | -32% | 9.34M | 1.5 |
| Sep 15, 2026 | 19.91M | 1.15% | -10% | 7.73M | 2.6 |
| Aug 31, 2026 | 22.13M | 1.28% | +9% | 8.30M | 2.7 |
| Aug 14, 2026 | 20.38M | 1.18% | -10% | 7.13M | 2.9 |
| Jul 31, 2026 | 22.62M | 1.31% | -9% | 13.63M | 1.7 |
| Jul 15, 2026 | 24.85M | 1.44% | +6% | 11.61M | 2.1 |
| Jun 30, 2026 | 23.39M | 1.35% | +6% | 15.81M | 1.5 |
| Jun 15, 2026 | 21.97M | 1.26% | -0% | 12.40M | 1.8 |
| May 29, 2026 | 22.04M | 1.27% | -5% | 11.37M | 1.9 |
| May 15, 2026 | 23.22M | 1.33% | +3% | 13.67M | 1.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded ABT
Since Nov 17, 2024, 19 members of Congress reported 17 purchases and 28 sales of ABT. The latest was a sale by Pete Sessions on Oct 2, 2026, reported Oct 27, 2026.
Purchases 17Sales 28
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Pete Sessions (R-TX) | Sale | $50K–$100K | Spouse | Oct 27, 2026 | Report |
| Sep 18, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Oct 12, 2026 | Report |
| Sep 17, 2026 | Thomas H. Kean, Jr. (R-NJ) | Partial sale | $1K–$15K | Self | Oct 30, 2026 | Report |
| Jul 30, 2026 | Richard McCormick (GA) | Sale | $1K–$15K | Self | Aug 14, 2026 | Report |
| Jul 17, 2026 | Mike Kelly (R-PA) | Sale | $1K–$15K | Spouse | Aug 12, 2026 | Report |
| Jul 14, 2026 | Rick W. Allen (R-GA) | Sale | $15K–$50K | Spouse | Aug 18, 2026 | Report |
| Jul 8, 2026 | Rick Larsen (D-WA) | Sale | $1K–$15K | Self | Jul 12, 2026 | Report |
| Jun 16, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Jul 2, 2026 | Report |
| Jun 12, 2026 | Richard McCormick (GA) | Purchase | $1K–$15K | Self | Jul 9, 2026 | Report |
| May 27, 2026 | Josh Gottheimer (D-NJ) | Partial sale | $1K–$15K | Joint | Jun 3, 2026 | Report |
| May 15, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Sale | $1K–$15K | Self | Jun 8, 2026 | Report |
| May 12, 2026 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | Jun 12, 2026 | Report |
| Apr 16, 2026 | Rick W. Allen (R-GA) | Sale | $15K–$50K | Spouse | Jun 5, 2026 | Report |
| Mar 27, 2026 | Alan Armstrong (R-OK) | Sale | $15K–$50K | Self | Jul 21, 2026 | Report |
| Mar 24, 2026 | Laura Friedman (D-CA) | Exchange | $1K–$15K | Self | Apr 17, 2026 | Report |
| Mar 19, 2026 | Richard McCormick (GA) | Purchase | $1K–$15K | Self | Apr 7, 2026 | Report |
| Feb 10, 2026 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Mar 9, 2026 | Report |
| Jan 29, 2026 | Thomas H. Kean, Jr. (R-NJ) | Purchase | $1K–$15K | Self | Feb 19, 2026 | Report |
| Dec 19, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Partial sale | $1K–$15K | Self | Jan 12, 2026 | Report |
| Dec 18, 2025 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | Jan 15, 2026 | Report |
| Dec 8, 2025 | Julia Letlow (R-LA) | Sale | $1K–$15K | Self | Jan 13, 2026 | Report |
| Dec 4, 2025 | Byron Donalds (R-FL) | Sale | $1K–$15K | Self | Jan 7, 2026 | Report |
| Dec 4, 2025 | Byron Donalds (R-FL) | Sale | $1K–$15K | Spouse | Jan 7, 2026 | Report |
| Nov 18, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Dec 15, 2025 | Report |
| Nov 13, 2025 | Julie Johnson (D-TX) | Partial sale | $1K–$15K | Joint | Dec 11, 2025 | Report |
| Nov 5, 2025 | Richard McCormick (GA) | Purchase | $1K–$15K | Self | Dec 9, 2025 | Report |
| Oct 6, 2025 | Rick Larsen (D-WA) | Purchase | $1K–$15K | Self | Oct 16, 2025 | Report |
| Aug 14, 2025 | Julie Johnson (D-TX) | Partial sale | $1K–$15K | Joint | Sep 11, 2025 | Report |
| Jul 21, 2025 | Thomas H. Kean, Jr. (R-NJ) | Purchase | $1K–$15K | Self | Aug 20, 2025 | Report |
| Jul 18, 2025 | Josh Gottheimer (D-NJ) | Partial sale | $1K–$15K | Joint | Aug 11, 2025 | Report |
| Jul 10, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 24, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| May 12, 2025 | Jefferson Shreve (R-IN) | Sale | $50K–$100K | Self | Jun 22, 2025 | Report |
| Apr 21, 2025 | Bruce Westerman (R-AR) | Sale | $1K–$15K | Self | May 12, 2025 | Report |
| Mar 20, 2025 | Byron Donalds (R-FL) | Purchase | $1K–$15K | Self | Apr 14, 2025 | Report |
| Mar 20, 2025 | Byron Donalds (R-FL) | Purchase | $1K–$15K | Spouse | Apr 14, 2025 | Report |
| Mar 6, 2025 | Josh Gottheimer (D-NJ) | Partial sale | $1K–$15K | Joint | Apr 10, 2025 | Report |
| Mar 3, 2025 | Bruce Westerman (R-AR) | Purchase | $1K–$15K | Self | Apr 16, 2025 | Report |
| Feb 24, 2025 | Shelley Moore Capito (R-WV) | Partial sale | $1K–$15K | Spouse | Mar 6, 2025 | Report |
| Feb 13, 2025 | Josh Gottheimer (D-NJ) | Purchase | $1K–$15K | Joint | Mar 6, 2025 | Report |
| Jan 29, 2025 | Josh Gottheimer (D-NJ) | Purchase | $1K–$15K | Joint | Feb 10, 2025 | Report |
| Jan 28, 2025 | Josh Gottheimer (D-NJ) | Purchase | $1K–$15K | Joint | Feb 10, 2025 | Report |
| Jan 15, 2025 | Jared Moskowitz (D-FL) | Sale | $1K–$15K | Self | Feb 10, 2025 | Report |
| Jan 15, 2025 | Jared Moskowitz (D-FL) | Sale | $1K–$15K | Child | Feb 10, 2025 | Report |
| Jan 6, 2025 | Emily Randall (D-WA) | Sale | $1K–$15K | Spouse | Feb 11, 2025 | Report |
| Dec 16, 2024 | Thomas H. Kean, Jr. (R-NJ) | Purchase | $1K–$15K | Self | Jan 22, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Abbott Laboratories company events
Abbott Laboratories filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 21, 2026.
- Oct 21, 2026AnnouncementFiled as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing that it plans to separate its global nutrition business into an independent, publicly traded company. Filing
- Oct 21, 2026ResultsReleased financial results. Filing
- Aug 20, 2026AnnouncementAs previously reported in Abbott’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, Abbott is a defendant in numerous lawsuits alleging that preterm infants developed necrotizing enterocolitis… Filing
- Jul 16, 2026ResultsReleased financial results. Filing
- Apr 27, 2026LeadershipKevin Conroy was named to the Abbott Laboratories’ Board of Directors. Filing
- Apr 17, 2026AnnouncementAs previously disclosed in Abbott’s Annual Reports on Form 10-K for the fiscal years ended December 31, 2024 and December 31, 2025, six shareholder derivative lawsuits have been pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation, before… Filing
- Apr 16, 2026ResultsReleased financial results. Filing
- Mar 23, 2026AnnouncementAbbott Laboratories, an Illinois corporation, completed the acquisition of Exact Sciences Corporation, a Delaware corporation, pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025, by and among Abbott, Exact Sciences and Badger Merger Sub I, Inc., a Delaware corporation and a… Filing
- Mar 9, 2026AgreementAbbott Laboratories completed the public offering and issuance of $20 billion of senior notes, consisting of $1 billion of its Floating Rate Notes due 2029, $2.25 billion of its 3.700% Notes due 2029, $2.5 billion of its 4.000% Notes due 2031, $2.75 billion of its 4.300% Notes due 2033, $3.75… Filing
- Feb 26, 2026AgreementAbbott Laboratories entered into a pricing agreement, dated February 23, 2026, by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein, pursuant… Filing
- Feb 20, 2026RulesChanged its bylaws or articles. Filing
- Jan 22, 2026ResultsReleased financial results. Filing
- Dec 12, 2025LeadershipNita Ahuja, M.D. was named to the Abbott Laboratories’ Board of Directors. Filing
- Nov 20, 2025AgreementAbbott Laboratories, an Illinois corporation, entered into an Agreement and Plan of Merger with Exact Sciences Corporation, a Delaware corporation, and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
How Abbott Laboratories makes money
Medical Devices brought in half of Abbott Laboratories's revenue ($21.4B of $44.3B) in 2025. Diagnostic Products was next, at 20%.
By business segment, 2025
By region, 2025
From Abbott Laboratories's annual report (10-K) for the year ended Dec 31, 2025, filed Feb 20, 2026. The company chooses how to group its revenue, so the parts differ from one company to the next. Read the filing · How the biggest companies make money
Abbott Laboratories financials
Famous investors that hold ABT
10 of the 50 well-known investors we track reported holding ABT in their latest 13F filing. The largest position is Jeremy Grantham's, worth $886M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jeremy Grantham · GMO | Q3 2026 | 8.97M | $886M | 1.9% | +2% |
| Israel Englander · Millennium Management | Q3 2026 | 2.10M | $207M | 0.2% | -42% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.84M | $182M | 0.3% | +19% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.70M | $168M | 0.1% | -80% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 467,019 | $46.2M | 0.0% | -8% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 458,466 | $45.3M | 0.1% | -33% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 55,789 | $5.5M | 0.0% | -7% |
| George Soros · Soros Fund Management | Q3 2026 | 44,750 | $4.4M | 0.1% | No change |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 16,099 | $1.6M | 0.0% | -98% |
| Tom Russo · Gardner Russo & Quinn | Q3 2026 | 11,510 | $1.1M | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Abbott Laboratories (ABT) stock
Who owns the most ABT stock?
The largest reported owner of Abbott Laboratories (ABT) is BlackRock, Inc., with 8.8% of the company. In total, 2,951 funds and institutions reported holding ABT at the end of Q2 2026, together about 80% of the shares. See the largest owners.
Are ABT insiders buying or selling?
In the last 12 months, ABT insiders reported 6 open-market purchases worth $4.4M and 12 sales worth $47.9M. The latest trade was on Nov 5, 2026. See every trade.
What is the short interest in ABT?
As of Oct 30, 2026, 19.06M ABT shares were sold short, 1.1% of the shares outstanding, up 9.6% from the report before. At the average daily volume of 9.96M shares, buying them all back would take about 1.9 trading days (days to cover). See the history.
Have members of Congress traded ABT?
Yes. 19 members of Congress reported 17 purchases and 28 sales of ABT since Nov 17, 2024. The latest was reported on Oct 30, 2026. See the trades.
How does Abbott Laboratories make money?
Medical Devices brought in half of Abbott Laboratories's revenue ($21.4B of $44.3B) in 2025. Diagnostic Products was next, at 20%. See the full split.
Which famous investors hold ABT?
10 of the 50 well-known investors we track reported ABT in their latest 13F filing, including Jeremy Grantham, Israel Englander, Steve Cohen. The largest position is worth $886M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.